3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Melanoma
4
Carcinoma, Basal Cell
4
Sarcoma, Kaposi
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Interventions
Doxorubicin
5
tecogalan
4
Liposomes
4
Vincristine
3
Semaxinib
3
Bleomycin
3
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
2
Alitretinoin
2
vesnarinone
1
tin etiopurpurin
1
daromun
1
Tumor Necrosis Factor-alpha
1
Ro 24-7429
1
Ritonavir
1
Quality of Life
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Nelfinavir
1
Molecular Diagnostic Techniques
1
Mitoxantrone
1
Immunotherapy
1
Drug Therapy
1
Daunorubicin
1
Brentuximab Vedotin
1
Biological Therapy
1
Bexarotene
1
4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone
1
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Sarcoma, Kaposi
×
daromun
×
Clear all
NCT05329792
2023-10-06
IntriNSiC
Philogen S.p.A.
Phase 2
Unknown
70 enrolled